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around  5.3%;  however,  previous  reports  have  shown  trends  of
increasing  incidence  rates.4 However,  in  our  study  we  found
a  lower  incidence  (3.2%).  Patients  who  developed  NSCLC  at
a  young  age  may  have  other  unknown  risk  factors  in  addition
to  inherited  risk.3
Adenocarcinoma  was  the  most  common  histopathological
type  in  this  group,  conﬁrming  previously  published  series.1--5
The  majority  of  patients  presented  with  advanced  stage  dis-
ease  at  diagnosis,  despite  a  good  PS.  Unfortunately,  for  most
of  the  study  period  the  patients  were  not  screened  for  driver
mutations  so  the  platinum-based  doublet  was  the  most  fre-
quently  used  treatment  scheme.  There  are  conﬂicting  data
regarding  prognosis  in  this  group  when  comparing  them  with
older  adults.1--5 In  our  study,  despite  the  aggressive  treat-
and survival in the English National Lung Cancer Audit. QJM
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hment,  the  prognosis  was  poor.
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Not yet known side effects of
pirfenidone in the treatment of
idiopathic pulmonary ﬁbrosis?
To  the  Editor,
Idiopathic  pulmonary  ﬁbrosis  (IPF)  is  a  speciﬁc  form  o
chronic,  progressive  ﬁbrosing  pneumonia  of  unknown  cause
occurring  primarily  in  older  adults  and  limited  to  th
lungs,1,2 with  a  very  poor  prognosis.
There  were  no  therapeutic  options  with  proven  efﬁ
cacy  until  recent  randomized  controlled  trials  have  show
the  efﬁcacy  of  pirfenidone  and  nintedanib  in  reducing  th
decline  rate  of  forced  vital  capacity  (FVC).3,4
Like  any  other  recently  introduced  drug,  the  whole  spe
trum  of  the  side  effects  of  pirfenidone  is  still  unknown
The  most  frequent  side  effects  reported  from  the  CAPACIT
and  ASCEND  trials,3,5 the  follow-up  extension  study  RECAP
and  PASSPORT  registry  interim  results,7 are  gastrointest
nal  (nausea,  diarrhea,  dyspepsia  and  vomiting),  cutaneou
(rash,  photosensitivity),  headache,  dizziness  and  fatigue
Although  cough,  upper  airway  tract  infection  and  worsen
ing  of  IPF  were  also  reported,  these  could  be  attributed  to
the  pathophysiology  of  IPF  per  se.
We  report  the  cases  of  2  patients  diagnosed  with  IPF
according  to  the  American  Thoracic  Society  (ATS)/European
Respiratory  Society  (ERS)/Japanese  Respiratory  Soci-
ety/ALAT  consensus  statement  on  IPF1 and  the  2013
ATS/ERS  update  of  the  International  MultidisciplinaryR.  Gomes , H.  Dabó , H.  Queiroga ,  V.  Hespanhol
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Classiﬁcation  of  the  Idiopathic  Interstitial  Pneumonia
statements,2 who  experienced  probable  toxicity  induced  b
pirfenidone.
The  ﬁrst  case  reports  a  62-year-old  female  non-smoke
diagnosed  with  IPF  (Possible  UIP  HRCT  and  UIP  patter
in  surgical  lung  biopsy)  in  03-2011,  being  started  on  N
acetylcisteine  600  mg  tid.  The  patient  was  started  o
pirfenidone  in  05-2014;  at  that  time  a  mild  restriction  wa
observed  (FVC:  75%,  1760  mL,  TLCO:  76.3%).  From  the  tim
she  was  started  on  pirfenidone,  she  complained  of  dyspep
sia,  increasing  dyspnea  (modiﬁed  Medical  Research  Counc
dyspnea  scale  [mMRC]  2--3),  cough  and  wheezing.  On  phy
ical  examination,  bilateral  basilar  crackles  and  expirato
wheezing  were  observed.  Blood  analysis  was  unremar
able  and  sputum  microbiological  exams  were  negative
Chest  radiography  was  similar  to  the  previous  ones.  Cardia
heart  failure  and  pulmonary  hypertension  were  pursued  an
excluded  by  echocardiogram,  and  NT  pro-BNP  was  with
normal  range.  After  4  months  on  pirfenidone  the  patien
kept  complaining  of  wheezing  since  the  beginning  of  th
drug  and  troublesome  cough  not  alleviated  by  opioids;  fun
tional  decline  was  observed  (relative  FVC  drop  of  10%,  wit
maintained  TLCO  value).  Pirfenidone  was  interrupted,  with
resolution  of  symptoms  after  one  month  and  improvement  of
FVC  back  to  basal  values.  Reintroduction  of  pirfenidone  was
attempted,  but  recurrence  of  symptoms  led  to  its  deﬁnitive
suspension.
The  second  case  reports  a  66-year-old  non-smoker
woman  diagnosed  with  IPF  in  07-2014  (Possible  UIP  HRCT,
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UIP  pattern  in  surgical  lung  biopsy).  She  had  mMRC  1
dyspnea  and  troublesome  cough.  At  the  time  she  started
pirfenidone,  FVC  was  69.2%  (1470  mL)  and  TLCO  was  65%.  In
the  six-minute  walk  test  (6-MWT)  walked  501  m  with  desat-
uration  (from  96  to  86%).  When  pirfenidone  was  started
there  were  complaints  of  astenia  and  mild  anorexia.  After
two  months  on  the  drug  the  patient  reported  increasing
fatigue,  anorexia  and  increased  dyspnea  on  exertion  (mMRC
3).  Physical  examination  showed  a  5  kg  weight  loss  and
pulmonary  auscultation  revealed  diffuse  bilateral  crack-
les.  Blood  panel  was  unremarkable,  with  normal  leukocyte
count  and  slightly  increased  C-reactive  protein  (1.02  g/dL).
Chest  HRCT  revealed  new  diffuse  ground  glass  attenuation,
besides  the  ﬁbrotic  background  already  known.  Pulmonary
thromboembolism  was  excluded  by  angio-CT.  A  ﬁberoptic
bronchoscopy  was  performed,  which  revealed  no  structural
changes.  Blood  cultures  were  negative  and  no  infectious
agents  were  identiﬁed  (bacteria,  respiratory  virus  and
Pneumocystis  jirovecii)  in  bronchial  lavage  samples.  FVC
decreased  to  55.2%  (1140  mL)  and  TLCO  to  55%.  Pirfenidone
was  stopped,  with  marked  improvement  in  the  dyspnea
and  constitutional  symptoms  in  2  weeks;  at  that  time  no
other  measures  were  taken.  After  this  time,  since  objec-
tive  functional  impairment  was  observed,  the  patient  was
treated  for  acute  exacerbation  with  pulsed  steroids  (methyl-
prednisolone  10  mg/kg/day  3  days  followed  by  prednisolone
0.5  mg/kg/day  with  gradual  reduction),  which  achieved  clin-
ical  and  functional  stability.
New  drugs  that  can  change  the  ominous  prognosis  of
IPF  have  recently  become  available.  As  with  any  recently
introduced  drug,  one  must  bear  in  mind  the  possibility
of  unreported  side  effects  like  the  ones  the  authors  have
described.
The  ﬁrst  case  describes  an  apparent  causality  between
the  use  of  pirfenidone  and  symptoms  of  wheezing  and  wors-
ening  dyspnea,  a  side  effect  not  reported  in  CAPACITY  and
ASCEND  trials.3,5 In  the  second  case,  clinical  and  functional
deterioration  and  new  ground  glass  opacities  in  HRCT  were
observed  and  other  frequent  causes  for  rapid  deterioration
were  excluded.  The  suspension  of  pirfenidone  led  to  rapid
clinical  improvement,  raising  the  possibility  of  pulmonary
toxicity  induced  by  this  drug.  Although  the  concomitant
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With  the  wider  use  of  these  new  drugs,  new  side  effects
will  certainly  be  increasingly  described.  The  knowledge  and
awareness  of  the  potential  side  effects  induced  by  this  new
drug  is  of  the  greatest  importance  in  order  to  identify  poten-
tially  dangerous  adverse  events.
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httent  of  an  acute  exacerbation  when  the  patient  was  started
 this  drug  cannot  be  completely  excluded,  the  clinical
provement  when  the  drug  was  discontinued  and  the  exclu-
n  of  other  possible  causes  for  rapid  deterioration  raises
 suspicion  of  an  exacerbation  induced  by  pirfenidone.
king  into  account  there  was  no  previous  description
any  case  of  lung  toxicity  induced  by  pirfenidone,  the
thors  considered  it  would  be  better  for  the  patient  to
at  this  event  as  an  acute  exacerbation  with  high  dose
roids.
To  the  best  of  the  authors’  knowledge  the  described  side
ects  attributable  to  the  use  of  pirfenidone  have  not  yet
en  reported.Neves
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